Cover Image
QR Code

Rifaximin for the treatment of hepatic encephalopathy.

PURPOSE: The use of rifaximin for the treatment of hepatic encephalopathy (HE) is reviewed. SUMMARY: HE is observed in approximately 50-70% of all patients with cirrhosis. Clinical manifestations of HE range from altered mental status to deep coma. Most manifestations of this syndrome are reversible...

Full description

Published in:American Journal of Health-System Pharmacy Vol. 65; no. 9; pp. 818 - 823
Main Authors: de Melo RT, Charneski L, Hilas O
Format: Journal Article
Published: Oxford University Press / USA 5/1/2008
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105741689&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105741689
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10792082
        1X3
      jtl: American Journal of Health-System Pharmacy
      issn: 10792082
      maglogo: N
    pubinfo:
      dt: 5/1/2008
      vid: 65
      iid: 9
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        105741689
        2009914593
        10.2146/ajhp070298
        NLM18436728
        105741689
      ppf: 818
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Rifaximin for the treatment of hepatic encephalopathy.
      aug:
        au:
          de Melo RT
          Charneski L
          Hilas O
        affil: New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell, New York, USA.
      sug:
        subj:
          Antiinfective Agents Therapeutic Use
          Hepatic Encephalopathy Drug Therapy
          Antiinfective Agents Adverse Effects
          Female
          Male
          Female
          Male
      ab: PURPOSE: The use of rifaximin for the treatment of hepatic encephalopathy (HE) is reviewed. SUMMARY: HE is observed in approximately 50-70% of all patients with cirrhosis. Clinical manifestations of HE range from altered mental status to deep coma. Most manifestations of this syndrome are reversible with medical treatment. Treatment measures focus on the resolution of ammonia accumulation and identification/ removal of precipitating factors. Lactulose has been the mainstay of HE treatment in the acute and chronic settings, though its use is limited by poor patient tolerance and compliance. Chronic administration of antibiotics has also proven to be effective in HE. Historically, neomycin or metronidazole has been used, but both carry the risk of serious adverse effects. Rifaximin is a nonabsorbed derivative of rifamycin with a broad spectrum of activity against aerobic and anaerobic gram-positive and gram-negative organisms. Clinical trials have compared rifaximin to lactulose or neomycin for the treatment of HE. Rifaximin shows a general trend toward better efficacy versus lactulose or neomycin. In addition, rifaximin seems to offer a better safety and tolerability profile than that of lactulose and possibly neomycin. CONCLUSION: While no randomized, placebo-controlled studies have assessed the efficacy and long-term safety outcomes of rifaximin in the treatment of HE, rifaximin has demonstrated better efficacy and safety profiles compared with lactulose and neomycin. Future studies should assess HE outcomes with more consistent indexes and measurements and should compare the efficacy and safety of rifaximin with those of metronidazole.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N